Citation:Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al 2015

Citation

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015 Oct;16(13):1306-15 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26338525.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Role of biological agents in first-line treatment of metastatic colorectal cancer
2. Systemic chemotherapy treatment options for first-line treatment